千金药业发布半年度业绩，归母净利润1.28亿元，同比增长8.5%

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) reported a decline in revenue for the first half of 2025, while net profit showed growth, indicating mixed performance in financial results [1] Financial Performance - The company achieved revenue of 1.818 billion yuan, a year-on-year decrease of 5.52% [1] - The net profit attributable to shareholders was 128 million yuan, reflecting a year-on-year increase of 8.5% [1] - The net profit after deducting non-recurring gains and losses was 118 million yuan, up by 6.58% year-on-year [1] - Basic earnings per share were reported at 0.3012 yuan [1]